New Delhi: Fresenius Kabi, a wholly-owned subsidiary of German health care group Fresenius SE, said on Monday, 21 April, it has no plans to delist Dabur Pharma after its acquisition of the Indian firm.
“It will continue to be traded,” Rainer Baule, president and CEO of Fresenius Kabi, told reporters.
Fresenius acquired 73.3% of anti-cancer drug maker Dabur Pharma for Rs8.78 billion ($219 million), or Rs76.50 a share, in cash on Saturday.
It said it would make a mandatory offer to acquire another 20% of the company within 4-6 weeks.
Fresenius Kabi, which provides patients in many countries in Europe with an outpatient nutrition therapy service, said the acquisition will broaden its offering of patient-specific oncology therapies and help it expand its drug portfolio.
Dabur operates two production facilities in India and one in Britain. It also has a research and development centre near New Delhi.
